41+ min ago  (113+ words) Onco Daily is a specialized news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by delivering timely and accurate insights into the latest…...

1+ hour, 40+ min ago  (500+ words) First results from the phase 2 ERASMM (EMN34, NCT06183489) study, evaluating elranatamab as an early therapeutic intervention in patients with high-risk smoldering myeloma, were presented by Cyrille Touzeau at ASCO 2026." The results provided insight into whether early intervention with elranatamab could achieve deep…...

6+ hour, 37+ min ago  (97+ words) Onco Daily is a specialized news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by delivering timely and accurate insights into the latest…...

1+ hour, 43+ min ago  (57+ words) Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post a post on Linked In: "So excited for my first ASCO. It's just incredible: the atmosphere, the vibes, the networking, the research, the science, the innovation. Honored…...

8+ hour, 28+ min ago  (257+ words) Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of Med News Week, shared a post on Linked In: "Clinical reasoning has long been considered one of the most complex and uniquely human aspects of medicine. Now, a new study suggests…...

8+ hour, 22+ min ago  (120+ words) Nicholas Hornstein, Assistant Professor at Northwell Health, shared Sawyer Bawek's, Junior Chief Fellow at Cleveland Clinic, post on X, adding: "Highlight of ASCO26 was being able to share a stage with these giants of GI Oncology that I've looked up to…...

8+ hour, 18+ min ago  (134+ words) Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X: "Can a "second-look" ct DNA test rescue patients who initially appeared low-risk after CRC surgery? The GALAXY study suggests yes. Patients with resected stage I-IV CRC who were: derived a…...

2+ hour, 58+ min ago  (347+ words) Updated results from the phase 3 SUNMO (NCT05171647), evaluating Mosun-Pola vs R-Gem Ox in R/R Large B-cell lymphoma, were presented by L. Elizabeth Budde, MD, Ph D. At the primary analysis, Mosun-Pola demonstrated superiority over R-Gem Ox, including improved response rates and PFS,…...

7+ hour, 38+ min ago  (113+ words) Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X: "Perioperative EV +pembo vs cystectomy (KN905) in MIBC shows great OS and p CR >50%. Quality of life data can be difficult to interpret due to multiple…...

2+ hour, 32+ min ago  (661+ words) OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly need adjuvant chemotherapy, and which patients can safely avoid it? Presented…...